Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study.

Abstract

In this prospective, open-label pilot study, we evaluated the safety and efficacy of etanercept, a TNF-alpha inhibitor, in the treatment of moderate to severe alopecia areata, alopecia totalis, or alopecia universalis. Seventeen otherwise healthy adults with moderate to severe alopecia areata were enrolled. The primary outcome measure was the extent of hair regrowth during and after the end of treatment as evaluated by the Severity of Alopecia Tool (the SALT score). After between 8 and 24 weeks of continuous treatment with etanercept 50 mg given subcutaneously twice weekly, significant regrowth of hair was not shown in any of the subjects treated. Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis.

• Authors: Bruce E Strober, Kimberly Siu, Andrew F Alexis, Gene Kim, Ken Washenik, Animesh Sinha, Jerome L Shupack
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 52 Issue 6 Pg. 1082-4 (Jun 2005) ISSN: 1097-6787 [Electronic] United States
• PMID: 15928633 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Etanercept

Topics

• Adult
• Alopecia Areata (drug therapy)
• Etanercept
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Male
• Middle Aged
• Pilot Projects
• Prospective Studies
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Severity of Illness Index
• Treatment Failure
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)